Story perspectives

Health Canada Issues Warning on Unauthorized GLP-1 Drugs

1/23/2026

33 7

Summary

Story summary

Health Canada warns against using unauthorized glucagon-like peptide-1 (GLP-1) drugs, such as semaglutide, due to serious health risks.
The advisory cites infections, allergic reactions, and contamination from counterfeit products.
Health Canada identified retailers selling unauthorized versions and cautioned consumers about misleading advertisements.
The agency is working with the Canada Border Services Agency to prevent unauthorized shipments.
Eight generic submissions for Ozempic and Wegovy are under review, potentially lowering prices.

1 of 1

Story summary

Health Canada warns against using unauthorized glucagon-like peptide-1 (GLP-1) drugs, such as semaglutide, due to serious health risks.
The advisory cites infections, allergic reactions, and contamination from counterfeit products.
Health Canada identified retailers selling unauthorized versions and cautioned consumers about misleading advertisements.
The agency is working with the Canada Border Services Agency to prevent unauthorized shipments.
Eight generic submissions for Ozempic and Wegovy are under review, potentially lowering prices.